News
We send the latest information from SMC Laboratories.
Lipocine announces positive topline Phase 2 results from LPCN1144 ongoing Lift study in biopsy-confirmed NASH subjects
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT study in biopsy-confirmed NASH subjects. For detailed information, see the below URL. https://www.lipocine.com/news-article/lipocine-announces-positive-topline-phase-2-results-from-lpcn-1144-ongoing-lift-study-in-biopsy-confirmed-nash-subjects/
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients. For detailed information, see the below URL. https://www.chemomab.com/uploads/pr-chemomab-spark-results.pdf CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the…
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For detailed information, see the below URL. https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial
CytoDyn announces first patient enrolled in Phase 2 study for NASH
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 study for NASH. For detailed information, see the below URL. https://www.cytodyn.com/newsroom/press-releases/detail/489/cytodyn-announces-first-patient-enrolled-in-phase-2-trial Leronlimab is a CCR5 agonist.We are looking forward to clinical results.
Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH
Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH. For detailed information, see the below URL. http://www.globenewswire.com/news-release/2020/10/12/2107044/0/en/Inventiva-receives-FDA-Breakthrough-Therapy-designation-for-lead-drug-candidate-lanifibranor-in-NASH.html Lanifibranor is a PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms (a, g, σ) This compound is also currently undergoing Phase…
Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~
Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Experience~ (November 13-16). For detailed information, see the below URL. https://aasldpubs.onlinelibrary.wiley.com/toc/15273350/2020/72/S1 Poster #554 Iron loss triggers mitophagy through induction of mitochondrial ferritin Institution: Kawasaki Medical School (Japan) Poster #568 Oxysterol transformation of fatty liver…
Virginia Comonwealth University's publication in Journal of lipid research
SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAMTM mouse model in Journal of lipid research. Title: “Insulin resistance dysregulateds CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition” In this paper, they report the involvement of CYP7B1 in the transition from NAFL…
University of Yamanashi's publication in Clinical and Experimental Gastroenterology
SMC announces that University of Yamanashi (Japan) has published the results of a study using STAMTM mouse model in Clinical and Experimental Gastroenterology. Title: “Changes in Function and Dynamics in Hepatic and Splenic Macrophages in Non-Alcoholic Fatty Liver Disease” In this paper, they report the involvement of liver and spleen macrophages in NASH…
Aldafermin improves fibrosis in patiants with NASH
NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its primary endpoint, achieving a statistically significant reduction in liver fat content, robust fibrosis improvement, and resolution of NASH, with a favorable safety profile. For detailed information, see the below URL. https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-presents-comprehensive-findings-24-week-phase-2-study It has been reported…
89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH
89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89-100 in patients with NASH. BIO89-100 treatment group demonstrated significant reductions in liver fat. For detailed information, see the below URL. https://ir.89bio.com/news-releases/news-release-details/89bio-announces-positive-topline-results-its-phase-1b2a-trial BIO89-100 is a FGF21 analog. Another FGF21 analog, Bristol-Myers Squibb's BMS-986036, is also currently undergoing…